U.S. PHARMACOPEIA

Search USP29  
Hydrocodone Bitartrate
Click to View Image
C18H21NO3·C4H6O6·2½H2O 494.490
Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5).
4,5-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) [34195-34-1; 6190-38-1].

Anhydrous 449.46 [143-71-5].
» Hydrocodone Bitartrate, dried in vacuum at 105 for 2 hours, contains not less than 98.0 percent and not more than 102.0 percent of C18H21NO3·C4H6O6.
Packaging and storage— Preserve in tight, light-resistant containers.
Identification—
A: Infrared Absorption 197M.
B: Ultraviolet Absorption 197U
Solution: 100 µg per mL.
Medium: 0.1 N sulfuric acid.
Specific rotation 781S: between –79 and –84.
Test solution: 20 mg, undried, per mL, in water. Calculate the result on the basis of the undried aliquot.
pH 791: between 3.2 and 3.8, in a solution (1 in 50).
Loss on drying— Dry it in vacuum at 105 for 2 hours [NOTE—See the Note in the Assay for precautions regarding handling of the dried material.]: it loses not less than 7.5% and not more than 12.0% of its weight.
Residue on ignition 281: not more than 0.1%.
Chloride— To 10 mL of a solution (1 in 100), acidified with nitric acid, add a few drops of silver nitrate TS: no opalescence is produced immediately.
(Postponed indefinitely)
Related compounds— [NOTE—For the test for Related compounds and in the Assay, dry both USP Hydrocodone Bitartrate RS and USP Dihydrocodeine Bitartrate RS under vacuum at 105 for 2 hours. Immediately transfer the dried materials to a desiccator containing phosphorus pentoxide. Immediately weigh each dried material.]
Solution A, Solution B, Mobile phase, and Chromatographic system— Proceed as directed in the Assay.
Test solution— Use the Assay preparation.
System suitability solution— Combine about 1.5 mg of USP Dihydrocodeine Bitartrate RS and 1.0 mL of the Standard preparation prepared for the Assay in a 200-mL volumetric flask. Dilute with Solution A to volume, and mix.
Chromatographic system (see Chromatography 621)— Proceed as directed in the Assay. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.89 for dihydrocodeine and 1.0 for hydrocodone; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Inject equal volumes (about 20 µL) of the Test solution and the System suitability solution into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the percentage of dihydrocodeine bitartrate and any unknown impurities in the portion of Hydrocodone Bitartrate taken by the formula:
10,000(C/W)F(rU / rS),
in which C is the concentration, in mg per mL, of USP Hydrocodone Bitartrate RS in the System suitability solution; W is the quantity, in mg, of Hydrocodone Bitartrate taken to prepare the Test solution; F is the relative response factor and is equal to the values given in the following table; rU is the individual peak response of each impurity in the test solution; and rS is the response of hydrocodone bitartrate in the System suitability solution: not more than 0.5% of any individual impurity is found, and not more than 2.0% of total impurities is found.
Hydrocodone Bitartrate
and
Related Compounds
Relative
Retention Time
Relative
Response
Factor
Dihydrocodeine bitartrate 0.89 0.81
Hydrocodone diol
bitartrate
0.92 0.76
Hydrocodone bitartrate 1.00 1.00
Dihydrothebainone
bitartrate
1.03
Hydrocodone aldol dimer
bitartrate
1.10 0.96
7-Cyclohexenyl hydroco-
done bitartrate
1.50 1.00
Benzophenone 1.79
Other impurities 1.0
(Postponed indefinitely)
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay— [NOTE—See the Note in the test for Related compounds before performing the Assay.]
Solution A— Dissolve 5.75 g of monobasic ammonium phosphate in about 900 mL of water in a 1000-mL volumetric flask, adjust with phosphoric acid to a pH of 3.0 ± 0.1, dilute with methanol to volume, and mix.
Solution B— Prepare a filtered and degassed mixture of methanol and water (80:20).
Mobile phase— Use variable mixtures of Solution A and Solution B as directed for Chromatographic system. Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation— Dissolve an accurately weighed quantity of USP Hydrocodone Bitartrate RS in Solution A to obtain a solution having a known concentration of about 1.5 mg per mL.
Assay preparation— Transfer an accurately weighed quantity of previously dried Hydrocodone Bitartrate, equivalent to about 150 mg of hydrocodone bitartrate, to a 100-mL volumetric flask, dissolve in and dilute with Solution A to volume, and mix.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L7. The column temperature is maintained at 60. The flow rate is about 1.2 mL per minute. The chromatograph is programmed as follows.
Time
(minutes)
Solution A
(%)
Solution B
(%)
Elution
0 100 0 equilibrium
0–6 100 0 isocratic
6–30 100®0 0®100 linear gradient
30–31 0®100 100®0 linear gradient
Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the tailing factor is not more than 1.0; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the quantity, in mg, of hydrocodone bitartrate (C18H21NO3·C4H6O6) in the portion of Hydrocodone Bitartrate taken by the formula:
100C(rU / rS),
in which C is the concentration, in mg per mL, of USP Hydrocodone Bitartrate RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
(Postponed indefinitely)
Auxiliary Information— Staff Liaison : Clydewyn M. Anthony, Ph.D., Scientist
Expert Committee : (MDCCA05) Monograph Development-Cough Cold and Analgesics
USP29–NF24 Page 1063
Pharmacopeial Forum : Volume No. 30(5) Page 1628
Phone Number : 1-301-816-8139